Fetal Bovine Serum Market Size, Share and Global Trend By Application (Drugs discovery, In-vitro fertilization, Vaccine production, Cell-based research, Diagnostics and biopharmaceutical manufacturing, Others), By End Users (Pharmaceutical & biotechnology companies, Contract Research Organizations (CRO), Academic and research organizations, Others) and Regional Forecast, 2024-2032

Fetal Bovine Serum (FBS) is derived from the blood of a bovine fetus with the help of closed collection system, generally at a slaughterhouse. The serum is generally used as a supplement to the basal growth medium in cell culture. The most common type of serum is fetal bovine serum (FBS) because of its high content of embryonic growth-promoting factors. In cell culture, the serum provides a wide variety of advantages such as low molecular weight nutrients, macromolecular proteins, carrier proteins of water-insoluble components, and other necessary compounds for the in vitro growth of cells, such as hormones and attachment factors.

A study published by the National Center for Biotechnology Information (NCBI), stated that the fetal bovine serum has experienced increased prices by greater than 300% due to the increased demand and limited availability. In January 2017, Nucleus Biologics launched its first ever premium cell culture product for the enabling of scientific breakthroughs in research & development.

One of the key market drivers responsible for the growth of the fetal bovine serum market is the increasing demand of fetal bovine serum for research & development initiatives across a number of fields, especially in the pharmaceutical and drug development domain. Combined with this, increasing the prevalence of acute and chronic diseases globally, and effectivity of fetal bovine serum is expected to boost the adoption of fetal bovine serum, which will eventually fuel the growth of the global fetal bovine serum market during the forecast period.

The factor that is expected to inhibit the growth of the global fetal bovine serum market is the growing ethical concerns associated with the collection of the fetal bovine serum. Some of the other factors that might inhibit the growth of the market are volatile pricing of the fetal bovine serum and the disparity across the various geographical segments from which the serum is sourced and collected.

Key Players Covered

Some of the major companies that are present in the global fetal bovine serum market are Thermo Fisher Scientific Inc., Merck KGaA, GENERAL ELECTRIC, Moregate Biotech, Atlanta Biologicals, Inc., Gemini Bio-Products, and Bovogen Biologicals Pty Ltd and other players.

SEGMENTATION

At present, in terms of application, drugs discovery and cell-based research are expected to hold a significant share of the global fetal bovine serum market owing to the higher efficiency of fetal bovine serum in drug discovery and cell-based research.

Key Insights

• Regulatory scenario for key countries


• Recent industry developments such as partnerships, mergers, and acquisitions


• Analysis of different fetal bovine serum types by treatment

Regional Analysis

The global fetal bovine serum market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for fetal bovine serum at present and they are expected to account for a larger proportion of the market during the forecast period. This is due to the reason that these regions hold huge populations of bovine and cattle to enable the production of fetal bovine serum and also the high proportion of the R&D activity undertaken. In the Asia Pacific, Australia is expected to provide the largest market opportunity owing to the huge proportion of the cattle population and favorable government support for research and development.

Key Industry Developments

• In July 2017, GE Healthcare and Oritain announced the launch of a testing service for the combatting of serum fraud.


• In January 2017, Nucleus Biologics launched the first ever premium fetal bovine serum for the enabling of the scientific breakthroughs while the R&D initiatives are being undertaken.


• In November 2014, InVitria launched the ZAP-SR (Serum Reducer), a product for the users of cell culture, who are currently using the fetal bovine serum (FBS) and are facing product shortages and escalating costs.